Danaher is at SLAS 2025
Booth #1619
Danaher is at SLAS 2025
Booth #1619
-
Date and Time
January 25 - 29, 2025
Featured Products
Agenda
Stay tuned for more talks and posters.
Sunday, January 26,2025
| Time | Type | Description | Room / Location | Presenter |
| 8:30 AM – 12:00 PM PST | Short Course | Level Up Your 3D Cell Culture: From Research to High Throughput In the last several years, multiple research publications have shown the increased value of using 3D cell models compared to traditional 2D systems. Although considered by many as a more representative model of in vivo biology, the setup of 3D models can be more challenging, especially when the throughput is increased. This course will provide an overview of scaffold and scaffold-free techniques and key optimizations for increased throughput through imaging technologies and automation. Attendees will learn the tips and tricks for improving cell seeding, handling, processing and use of high-content imaging and analysis for 3D applications to address the need of higher throughput demands.
Molecular Devices. | 28A | Angeline Lim, Oksana Sirenko, Hilary Sherman |
Monday, January 27,2025
| Time | Type | Description | Room / Location | Presenter |
| 12:00 PM – 1:00 PM PST | Poster | The development and optimization of a 384-well ELISA platform using CaptSure technology Poster# 1292-A
Abcam | Timothy Esch | |
| 2:00 PM – 3:00 PM PST | Exhibitor Tutorial | 85% Faster Through Automated Data Analysis: Development of an Automated Neutralization Assay Automation promises a drastic reduction in development and analysis time, reduce derror rates, and process optimization, leading to faster decision-making. In this tutorial, our partners at Moderna demonstrate how they developed an automated SARS-CoV-2neutralization assay, including the automation of the complete wet lab workflow with a complex integration of various lab automation hardware components and analysis instruments.For data analysis, they use Genedata Screener to automatically evaluate assay performance and automate data analysis, ensuring robust, high-quality data is ready for reporting. This results in an 85%-time savings in the data analysis and reporting process. Vikram Rao and Nicholas J. Amato will present how Moderna achieved this. Please read the full abstract of their excellent work below:'Development and Automation of a SARS-CoV-2 Neutralization Assay'The SARS-CoV-2 neutralization assay is a critical tool for assessing antibody efficacy against SARS-CoV-2 viruses in samples such as but not limited to sera from human and animals. This assay serves as an efficient means of assessing immune response for vaccine evaluations against virus variants under BSL-2 laboratory conditions.Traditionally, the in-house developed manual assay is a three-day, cell-based procedure that is labor-intensive and time-consuming.To address these challenges, we developed the company’s first automated cell-basedSARS-CoV-2 neutralization assay using an enclosed liquid handler, the HamiltonVantage, integrated with a BioTek plate washer, a Liconic incubator, and a BMGPHERAstar plate reader. Given the number of various peripherals and the limited sample volumes, we focused on creating a robust method that can accommodate various scenarios that minimizes run failures. By maximizing the capabilities of theVenus software on the Vantage and integrating it with our in-house application,Robotics, we enhanced recovery that allowed users to recover the assay from most error states of the automated protocol. Additionally, this system enables customization based on specific assay parameters.Following development, we executed assay validation studies, comparing data trends between the automated method and the manual assay, yielding results that demonstrate the automated and manual assays are comparable. The automated method can accommodate up to 18 assay plates in a single run, and up to two runs within a standard eight-hour workday. This automation reduces operator repetitive Confidential - Company Proprietary stress, streamlines the assay workflow and limits manual intervention, thereby saving overall operator time.Extending the assay automation, we collaborated with Genedata to develop a custom workflow in their Screener software that automates the data analysis portion of this assay, which is inherently complex. Automation minimizes the need to manually handle the data, preventing data management errors. The data analysis template loads the raw data, along with respective mapping metadata directly from the plate reader. Screener automatically evaluates assay performance following established criteria, ensuring robust, good quality data is readily available in a custom reportable format. This enables both short-term scientific decision making and long-term data trending, yielding an 85% time-savings relative to the manual data analysis and reporting process.Co-Authors: Sharanya Iyer, Diana Lee, Cindy Nguyen, Jose Garcia Condori, Lyndon Matsubara, Kalpesh Gupta, Kai Wu
Genedata | 28B | Nicholas J. Amato, Senior Director & Vikram Rao, Principal Research Associate, Moderna & Sascha Fischer, Business Development Manager |
| 2:00 PM – 3:00 PM PST | Poster | Efficient CCND1 Knockout, Colony Selection, and Screening via a Mammalian Colony Picker and Automated Cell Culture platform Poster # 1137-B
Molecular Devices | Oksana Sirenko | |
| 2:00 PM – 3:00 PM PST | Poster | High speed phenotypic profiling using a next generation high content imaging platform Poster #: 1273-B
Molecular Devices | Angeline Lim | |
| 2:00 PM – 3:00 PM PST | Poster | Use of AI-analysis tools and next generation High Content Screening Platform to improve data capture with 3D screening assays Poster #: 1257-B
Molecular Devices | Zhisong Tong | |
| 2:00 PM – 3:00 PM PST | Poster | Next-generation acoustic ejection mass spectrometry: A fully automated platform for high throughput sample analysis Poster #: 1225-B
Beckman Coulter Life Sciences & SCIEX | Sarah Simons, | |
| 4:00 PM – 4:30 PM PST | Scientific Talk | Targeting RNA to drug 'undruggable' targets using Evotec’s High-throughput RT-qPCR platform: focus on RNA splicing modulators Only a limited number of disease-relevant protein targets are considered druggable by small molecules. Thus, it remains critical to find alternative strategies for “undruggable” targets. In most cases, the goal is to decrease the amount of the target to abolish its activity. Two main strategies are favored: induction of the target degradation or inhibition of the target expression. This latest approach can be reached by decreasing the messenger RNA (mRNA) coding for the target. In multicellular eukaryotes, introns are removed from pre-mRNA and exons are stitched together to produce mature mRNA transcript, used downstream as a template for protein translation. This essential step, called pre-mRNA splicing, is a key regulatory step in gene expression. RNA splicing defects can lead to mutations and is associated with a large array of diseases, including cancers or Duchenne muscular dystrophy (DMD). There are currently two main classes of validated RNA-splicing therapeutics: antisense oligonucleotides (ASOs) as well as small molecules. Risdiplam has been the first approved small molecule splicing modulator for spinal muscular atrophy (SMA), and several ASO-based therapies have been approved by the U.S. Food and drug Administration (FDA) for the treatment of DMD, such as Nusinersen or Viltolarsen. Lately, interfering with mRNA splicing has become a new avenue to drug “undruggable” proteins. The goal is to modulate expression of pathogenic proteins by generating alternatively spliced RNA isoforms, that will lead to production of truncated and non-functional proteins or RNA degradation by nonsense-mediated mRNA decay (NMD) pathway. Quantitative reverse transcription PCR (RT-qPCR) is the gold standard to identify and profile RNA splicing modulators. At Evotec, we can leverage our fully automated multiplex RT-qPCR platform to accelerate identification of small molecule or ASO modulators of RNA splicing. RT-qPCR is compatible with the most advanced cell models such as primary cells, induced pluripotent stem cells or organoids. Our current optimized RT-qPCR process, miniaturized to 384-well plate format, allows to screen up to 13,000 compounds per day and to follow up to 4 genes in a single well by multiplexing. It thus represents a cost-effective alternative to reporter-gene assays. In addition to process automation, we present a highly scalable and automated data analysis workflow using Genedata Screener software. This software is used for rapid characterization of large sets of molecules to identify splicing modulators, highlight cytotoxic compounds and estimate compound activity from changes in concentration-response curves. Finally, gene expression hits are typically confirmed via different protein-based assays, such as HTRF or HiBit tagging system. Evotec has a strong track record at developing customized RT-qPCR assays and supported screening and profiling activities on dozens of RNA splicing targets.
Genedata | 30DE | Mélanie Carquin, Research Scientist, Team Leader, Evotec |
Tuesday, January 28,2025
| Time | Type | Description | Room / Location | Presenter |
| 8:30 AM – 10:00 AM PST | Exhibitor Tutorial | Revolutionizing Mass Spectrometry: High-Speed, Low-Sample Volume Acoustic Ejection for High-Throughput Sample Analysis Join us for a breakfast seminar featuring three distinguished experts discussing the Echo® MS+ system and its impact on high-throughput sample analysis. Discover innovative approaches from small molecules to intact proteins.
SCIEX | 24C | Adhi Tiwari, Sr. Scientist, Ginkgo Bioworks Daniel Blair, Assistant Member, St. Jude Children's Research Hospital Maxim Zhgamadze, Sr. Scientist, Johnson & Johnson |
| 12:00 PM – 1:15 PM PST | Exhibitor Tutorial | Automation of 3D organoid culture and assays powered by machine-learning and advanced image analysis The majority of developing drugs fail in the later stages of the drug development pipeline and in clinical trials because of the insufficient predictivity of cell models used to screen drug candidates. Organoid technologies appeared as a game-changer in disease modeling and drug screening, since they better resemble tissue structure and functionality and show more predictive response to drugs.
Molecular Devices | 28A | Oksana Sirenko, Ph.D. |
| 12:00 PM – 1:00 PM PST | Poster | Machine-learning assisted automation of complex 2D and 3D cell culture and assay models Poster# 1054-C
Molecular Devices | Oksana Sirenko | |
| 12:00 PM – 1:00 PM PST | Poster | Getting more information from organoids: A high-throughput assay for human alanine transaminase (hALT) Poster #: 1294-C
Molecular Devices | Cathy Olsen | |
| 12:00 PM – 1:00 PM PST | Poster | Leveraging covalent ligands as tool molecules in competition assay to enable hit finding and validation
Genedata | Jing Xue, Scientist 2, Genentech | |
| 12:00 PM – 1:00 PM PST | Poster | Ultra-high throughput HILIC-free analysis of oligonucleotides using acoustic ejection mass spectrometry Poster # 1226-C
SCIEX | Jacob McCabe, SCIEX | |
| 12:00 PM – 1:15 PM PST | Exhibitor Tutorial | SureFire and SimpleStep ELISA: High sensitivity screening platforms powered by recombinant antibody technology In this talk, we’ll delve into the advantages of SimpleStep ELISA technology, which combines the specificity of recombinant antibodies with the CaptSure immobilization technology. We’ll highlight innovation in high-throughput immunoassays, with a particular focus on SureFire® – the pharmaceutical industry’s go-to platform for high-throughput screening in drug discovery research – as well as a new 384-well format of SimpleStep ELISA. Finally, we’ll examine how our immunoassays effectively solve specific customer challenges, enhancing research efficiency and precision within the field
Abcam | 28B | Jeff Monette, Head of Immunoassay Platforms & Ant Sheehan, Director of Immunoassays |
| 2:00 PM – 3:00 PM PST | Poster | AI-enabled automated compound screening for toxicity effects using healthy intestinal organoids Poster # 1123-D
Molecular Devices | Oksana Sirenko | |
| 2:00 PM – 3:00 PM PST | Poster | Revolutionary Hit Finding Approach: Affinity-Based Screening Using High Throughput Spectral Shift Poster # 1023-D
Genedata | Vanessa Porkolab, Ph.D., Biophysics Director, Eurofins Cerep | |
| 2:00 PM – 3:00 PM PST | Poster | High-speed compound quality assessment using acoustic ejection mass spectrometry Poster # 1227-D
SCIEX | Jacob McCabe, SCIEX | |
| 2:00 PM – 3:00 PM PST | Exhibitor Tutorial | Automating Hit Finding of Covalent Inhibitors: A Mass Spectrometry Workflow The identification of covalent inhibitors has emerged as a promising approach for drug discovery due to their ability to form irreversible bonds with target proteins, leading to prolonged therapeutic effects. This tutorial will demonstrate a Rapid Fire based High-Throughput Screening (HTS) methodology for the detection of covalent inhibitor adducts, streamlining the drug discovery process. Utilizing advanced Quadrupole Time of Flight Mass Spectrometry coupled with automated liquid handling systems, the platform enables the swift identification of covalent interactions between small-molecule inhibitors and target proteins. By integrating novel Genedata data analysis algorithms, the method achieves high sensitivity and specificity, detecting subtle modifications in protein adduct formation. This approach accelerates the discovery of selective covalent inhibitors.
Genedata | 28B | Yecenia Peraza, Scientist, Pfizer |
Wednesday, January 29,2025
| Time | Type | Description | Room / Location | Presenter |
| 1:30 PM – 2:00 PM PST | Scientific Talk | Accelerating Early Drug Discovery: The Power of Integrated Data Systems and AI The early stages of drug discovery are crucial yet time-consuming and resource-intensive. With the rapid growth of data from various sources like high-throughput screening, omics technologies, and public databases, there is an immense opportunity to accelerate this process through integrated data management systems and artificial intelligence (AI). At Merck Healthcare KGaA, Darmstadt, Germany, we have developed a comprehensive platform that seamlessly integrates multi-modal data from diverse domains such as chemistry, biology, and pharmacology. This centralized data lake, coupled with robust data governance and quality control measures, ensures data integrity and accessibility for downstream analyses. Leveraging this integrated data ecosystem, we have implemented cutting-edge AI and machine learning models to drive key drug discovery activities. For instance, we employ deep learning techniques for virtual screening, significantly increasing chemical diversity while simultaneously reducing the number of compounds to be tested experimentally. Additionally, our predictive models can accurately forecast key pharmacokinetic and toxicity parameters, enabling early prioritization of promising candidates. By tightly integrating AI with our unified data infrastructure, we aim to seamlessly traverse the entire drug discovery pipeline, from target identification and validation to hit discovery and lead optimization. This synergistic approach has already yielded tangible results, reducing cycle times and costs associated with early-stage drug discovery efforts. In this presentation, we will showcase key components of our pioneering framework, and demonstrate the transformative potential of integrated data systems and AI in accelerating the arduous journey of bringing life-changing therapies to patients.
Genedata | 30ABC | Bolek Zapiec; Head of Digital & Data Science; Merck Healthcare KgaA |
| 2:00 PM – 2:30 PM PST | Scientific Talk | SPR Binding Data Management for Biotherapeutic Development and AI/ML Training Generative biology incorporates cutting edge biology, high throughput automation and AI to speed up drug development. It’s critical to provide meaningful data to feed machine learning models and to predict developability of the therapeutic candidates. To adapt to the demands of larger sample size and shorter turnaround time, we are transforming our SPR binding assays, including automated assay plate preparation and customized data analysis module in Genedata Screener.
Genedata | 31ABC | Wei Wang, Senior Principal Scientist, Amgen |